For help on how to get the results you want, see our search tips.
578 results
Categories
Human Remove Human filter
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Paediatric investigation plans Remove Paediatric investigation plans filter
Medicine type
Biosimilar Remove Biosimilar filter
Additional monitoring Remove Additional monitoring filter
Generic Remove Generic filter
Accelerated assessment Remove Accelerated assessment filter
Authorisation status
Authorised Remove Authorised filter
-
List item
Human medicine European public assessment report (EPAR): Matever (updated)
levetiracetam, Epilepsy
Date of authorisation: 03/10/2011,
, Revision: 22, Authorised, Last updated: 31/03/2021
-
List item
Human medicine European public assessment report (EPAR): Pioglitazone Teva Pharma (updated)
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 26/03/2012,, Revision: 12, Authorised, Last updated: 31/03/2021
-
List item
Human medicine European public assessment report (EPAR): Lenalidomide Mylan (updated)
lenalidomide, Multiple Myeloma
Date of authorisation: 18/12/2020,, Revision: 1, Authorised, Last updated: 31/03/2021
-
List item
Human medicine European public assessment report (EPAR): Epclusa (updated)
Sofosbuvir, velpatasvir, Hepatitis C, Chronic
Date of authorisation: 06/07/2016,
, 
, Revision: 14, Authorised, Last updated: 31/03/2021
-
List item
Human medicine European public assessment report (EPAR): Hulio (updated)
adalimumab, Hidradenitis Suppurativa, Psoriasis, Crohn Disease, Uveitis, Arthritis, Rheumatoid, Colitis, Ulcerative, Spondylitis, Ankylosing, Arthritis, Psoriatic
Date of authorisation: 16/09/2018,, 
, Revision: 5, Authorised, Last updated: 30/03/2021
-
List item
Human medicine European public assessment report (EPAR): Comirnaty (updated)
Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2, COVID-19 virus infection
Date of authorisation: 21/12/2020,, 
, Revision: 4, Authorised, Last updated: 30/03/2021
-
List item
Human medicine European public assessment report (EPAR): COVID-19 Vaccine Moderna (updated)
CX-024414 (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2), COVID-19 virus infection
Date of authorisation: 06/01/2021,, , Revision: 1, Authorised, Last updated: 30/03/2021
-
List item
Human medicine European public assessment report (EPAR): Trazimera (updated)
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 26/07/2018,, , Revision: 7, Authorised, Last updated: 29/03/2021
-
List item
Human medicine European public assessment report (EPAR): Cometriq (updated)
cabozantinib, Thyroid Neoplasms
Date of authorisation: 21/03/2014,, 
, , Revision: 21, Authorised, Last updated: 29/03/2021
-
List item
Human medicine European public assessment report (EPAR): Ocrevus (updated)
ocrelizumab, Multiple Sclerosis
Date of authorisation: 08/01/2018,, Revision: 10, Authorised, Last updated: 29/03/2021
-
List item
Human medicine European public assessment report (EPAR): Axumin (updated)
Fluciclovine (18F), Prostatic Neoplasms, Radionuclide Imaging
Date of authorisation: 21/05/2017,, Revision: 11, Authorised, Last updated: 25/03/2021
-
List item
Human medicine European public assessment report (EPAR): Staquis (updated)
Crisaborole, Dermatitis, Atopic
Date of authorisation: 27/03/2020,, Revision: 3, Authorised, Last updated: 25/03/2021
-
List item
Human medicine European public assessment report (EPAR): Telmisartan Teva (updated)
telmisartan, Hypertension
Date of authorisation: 25/01/2010,, Revision: 11, Authorised, Last updated: 25/03/2021
-
List item
Human medicine European public assessment report (EPAR): Zoledronic Acid Hospira (updated)
zoledronic acid monohydrate, Hypercalcemia
Date of authorisation: 19/11/2012,, Revision: 17, Authorised, Last updated: 25/03/2021
-
List item
Human medicine European public assessment report (EPAR): Strensiq (updated)
asfotase alfa, Hypophosphatasia
Date of authorisation: 28/08/2015,, , 
, Revision: 14, Authorised, Last updated: 25/03/2021
-
List item
Human medicine European public assessment report (EPAR): Lenvima (updated)
lenvatinib mesilate, Thyroid Neoplasms
Date of authorisation: 28/05/2015,, , Revision: 15, Authorised, Last updated: 25/03/2021
-
List item
Human medicine European public assessment report (EPAR): Deferiprone Lipomed (updated)
Deferiprone, Iron Overload, beta-Thalassemia
Date of authorisation: 19/09/2018,, Revision: 3, Authorised, Last updated: 25/03/2021
-
List item
Human medicine European public assessment report (EPAR): Lemtrada (updated)
alemtuzumab, Multiple Sclerosis
Date of authorisation: 12/09/2013,
, , Revision: 11, Authorised, Last updated: 25/03/2021
-
List item
Human medicine European public assessment report (EPAR): Bortezomib Fresenius Kabi (updated)
bortezomib, Multiple Myeloma
Date of authorisation: 14/11/2019,, Revision: 4, Authorised, Last updated: 24/03/2021
-
List item
Human medicine European public assessment report (EPAR): Rizmoic (updated)
Naldemedine tosilate, Constipation
Date of authorisation: 18/02/2019,, Revision: 5, Authorised, Last updated: 24/03/2021
-
List item
Human medicine European public assessment report (EPAR): Bortezomib Hospira (updated)
bortezomib, Multiple Myeloma
Date of authorisation: 22/07/2016,, Revision: 10, Authorised, Last updated: 24/03/2021
-
List item
Human medicine European public assessment report (EPAR): Bortezomib Accord (updated)
bortezomib, Multiple Myeloma
Date of authorisation: 20/07/2015,, Revision: 9, Authorised, Last updated: 24/03/2021
-
List item
Human medicine European public assessment report (EPAR): Giapreza (updated)
Angiotensin II acetate, Hypotension, Shock
Date of authorisation: 23/08/2019,, Revision: 1, Authorised, Last updated: 23/03/2021
-
List item
Human medicine European public assessment report (EPAR): Ambrisentan Mylan (updated)
ambrisentan, Hypertension, Pulmonary
Date of authorisation: 20/06/2019,, Revision: 2, Authorised, Last updated: 23/03/2021
-
List item
Human medicine European public assessment report (EPAR): Vidaza (updated)
azacitidine, Myelodysplastic Syndromes
Date of authorisation: 17/12/2008,, Revision: 21, Authorised, Last updated: 23/03/2021